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Objective: Restenosis is a limitation of endovascular interventions performed in the superﬁcial femoral artery (SFA).
Preclinical studies have demonstrated that the perivascular delivery of tissue-engineered allogeneic aortic endothelial cells
(PVS-10200) reduced stenosis in porcine models of SFA revascularization. The purpose of this study was to investigate
the safety and feasibility of percutaneous PVS-10200 delivery after angioplasty and stenting in the SFA of patients with
peripheral artery disease.
Methods: In this phase I open-label trial, 21 patients (average lesion length of 10.10 6 2.36 cm and $70% stenosis) were
treated with PVS-10200: 11 in a low-dose cohort (cohort A) and 10 in a high-dose cohort (cohort B). The primary
objective was to demonstrate the safety (incidence of major adverse events) of PVS-10200 within 4 weeks after surgery.
Secondary end points included assessments of resting ankle-brachial index (ABI) in the treated leg, Fontaine class, and
time to target lesion revascularization (TLR).
Results: No patient had a major adverse event within 4 weeks. One patient required a limb amputation at 30 weeks. At
48 weeks, cohort A and cohort B patients maintained a 37% and 62% increase in ABI compared with baseline, respectively;
70% of cohort A and 78% of cohort B improved by $1 Fontaine classiﬁcation stage, and the TLR rate was 39% for cohort
A and 20% for cohort B.
Conclusions: Percutaneous local delivery of PVS-10200 is a well-tolerated and novel therapeutic approach that may be a
suitable treatment for patients after endovascular intervention of the SFA. Larger randomized trials are needed to
determine if PVS-10200 can improve ABI and reduce TLR rates. (J Vasc Surg 2014;59:1597-606.)Interventional treatment for superﬁcial femoral artery Vascular restenosis is a complex response to injury
(SFA) lesions is widely accepted, resulting in more than
2 million total procedures performed annually world-
wide.1,2 Balloon angioplasty is used to revascularize the
SFA; however, restenosis rates of 40% to 60% in treated
segments have been observed after 1 year.3,4 Endovascular
stenting is used to improve the revascularization outcome.
Despite initial technical success, 1-year patency rates in
the SFA range between 22% and 61% after bare-metal
stent implantation.5-8 Treatment of extensive disease (eg,
lesions longer than 10 cm) is associated with even more
dramatic 1-year restenosis rates of >70%.3 The use of
drug-eluting stents in peripheral arteries has demonstrated
some beneﬁt to restenosis rates; however, long-term data
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effects of local injury, platelet adhesion and aggregation,
inﬂammation, and smooth muscle cell (SMC) prolifera-
tion can result in obstructive vascular lesions.13,14 Endo-
thelial cells (ECs), the major regulatory cells of the
blood vessel, reside not only at the lumen interface of
the affected vessel but also within the adventitia and
throughout the vessel as vasa vasorum. The endothelium
plays a central role in maintaining vascular integrity and
promoting healing after injury by producing and supply-
ing compounds that have the capacity to regulate vascular
physiology. These compounds include prostaglandins, ni-
tric oxide, endothelins, glycosaminoglycans such as hep-
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Fig 1. Perioperative angiograms obtained during a revascularization procedure of a typical enrolled patient. A, Initial
angiogram depicts an 8-cm-long occlusion of the right superﬁcial femoral artery (SFA; between white arrows). B, Final
angiogram after revascularization and stenting of the occlusion. C, Perioperative radiograph of the 10-cm-long nitinol
stent implanted in the right SFA.
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1598 Sevestre et al June 2014as transforming growth factor-b1 (TGF-b1), and other
vasoreactive agents15-18 Damage to the blood vessel and
endothelium that occurs after any vascular intervention
creates an imbalance in a cascade of signaling pathways
that often results in vascular pathologies such as throm-
bosis and restenosis. It was postulated that supplementing
the adventitia of an injured blood vessel with healthy ECs
may provide control over the response to vascular injury.
The use of EC-based therapy as a method to re-
endothelialize damaged vessels or to provide paracrine
control through perivascular implantation after vascular
intervention has been under investigation for some
time.19-23 The data suggest that surgically implanted allo-
geneic ECs cultured on gelatin matrices perivascular to
injured blood vessels inﬂuence the vessel response in pre-
clinical and clinical studies.21-25
A recent study investigated the use of an ultrasound-
guided visualization technique to minimally invasively
deliver perivascular allogeneic ECs on gelatin particles to
stented porcine femoral arteries.26 Signiﬁcantly greater
lumen diameter and a decrease in stenosis were observed
in the stented segments of arteries treated with ECs
compared with controls. Development of the minimally
invasive technique to safely deliver viable, functional cells ex-
pands the opportunity for the clinical application of cell-
based therapy subsequent to endovascular interventions for
peripheral arterial disease (PAD). In this study, we investi-
gated the safety, feasibility, and effects of ultrasound-
guided, percutaneous delivery of two doses of allogeneicECs cultured on gelatin particles (PVS-10200) in patients
undergoing revascularization of the SFA.
METHODS
Study design. The trial was an open-label, dose-esca-
lation, safety study of PVS-10200 conducted at three
participating sites in France (clinicaltrials.gov registration
number: NCT01099215). The study was completed
sequentially in two dose cohorts: cohort A, low-dose PVS-
10200 (6  105 cells/cm lesion), and cohort B, high-dose
PVS-10200 (15  105 cells/cm lesion). An independent
data safety monitoring board performed an ongoing review
of all safety reports and a formal review of patients in cohort
A at 4 weeks after surgery and recommended enrollment of
patients in cohort B. The sample size was considered
appropriate for a phase 1 study to collect information
regarding the safety of the investigational product and
feasibility of the delivery technique for this indication.
Study patients. The institutional review board at each
of the participating sites approved the protocol, and all study
patients provided written informed consent. All study pro-
cedures were performed in accordance with the guidelines
of the Declaration of Helsinki (1964) and subsequent revi-
sions. Individuals $18 years of age with symptomatic
PAD involving the SFA (deﬁned as Fontaine class IIb, III,
or IV) were eligible for enrollment. In addition, the
following requirements must have been met at the time of
intervention: stenosis of $50% or occlusion of the SFA;
target lesion length of 7-15 cm; and $1 patent (ie, <50%
Fig 2. Images depict ultrasound-guided percutaneous delivery of PVS-10200 adjacent to stented superﬁcial femoral
artery (SFA). All PVS-10200 injections were performed without complications, with an average approximate time to
complete the injections of less than 5 minutes. A,Color Doppler ultrasound shows a longitudinal view of the stented SFA.
B, The arrow points to the echogenic needle introduced at the level of the perivascular tissue. C, Longitudinal view imm-
ediately after the perivascular injection of PVS-10200.D, Transverse view of the perivascular injection of PVS-10200.
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been receiving a therapeutic dose of statin therapy starting at
least 7 days before intervention and continuing for at least
4 weeks after intervention. Major exclusion criteria included
acute limb ischemia; prior revascularization of the target
lesion; untreated inﬂow disease of the ipsilateral pelvic ar-
teries (>50% stenosis or occlusion); location of the target
lesion within an aneurysm or associated with an aneurysm
in the vessel segment either proximal or distal to the target
lesion(s); unresolved thrombus within the target vessel; a
hemorrhagic stroke#6months before the study procedure;
and additional percutaneous cardiac/peripheral interven-
tional procedures planned #30 days after the study
procedure.
Investigational product. PVS-10200 is being devel-
oped as a novel cell therapy product for use after minimally
invasive vascular interventions and is composed of allogeneic
aortic ECs cultured on gelatin powder (Gelfoam; Pﬁzer,
New York, NY). The human ECs, isolated from the aorta
of a single cadaver donor, were tested extensively for EC pu-
rity, biological function (assays for secretion of HS, TGF-b1
and ﬁbroblast growth factor, uptake of acetylated low-
density lipoprotein, and the ability to inhibit cultured
SMC proliferation), the presence of bacteria, fungi, known
human pathogens, and other adventitious agents accordingto established regulatory guidelines.27,28 The cells were
cryopreserved for later expansion and formulation on gelatin
powder, as previously described.26,29 Because of a limited
shelf life, multiple lots of PVS-10200 were used to treat 21
subjects in this study; however, all lots were formulated with
the use of ECs from the same aortic donor.
PVS-10200 was supplied to the clinical sites as a sus-
pension in sterile syringes and was transferred to custom-
ized delivery syringes that allowed for PVS-10200
concentration immediately before administration. Before
shipment to the clinic, PVS-10200 was tested for sterility
and endotoxin and assayed for cell number, viability, and
secreted levels of HS and TGF-b1. Each PVS-10200 dose
contained approximately 9.11  104 6 2.13  104 human
aortic ECs ($90% viability) per milligram of gelatin pow-
der, secreting levels of 0.84 6 0.33 mg/mL per day HS
and 760 6 273 pg/mL per day TGF-b1.
Study procedures. Patients were screened for study
participation within 30 days of their planned surgery. Anti-
platelet and statin therapies were initiated before surgery,
and patients underwent percutaneous transluminal an-
gioplasty and self-expanding nitinol stent placement
procedures according to the institutions’ standard of care
(Fig 1). Stents were implanted to extend 10 mm proximally
and distally from the margins of the target lesion(s), with
Table I. PVS-10200 dose escalation scheme for 21 enrolled patients
Cohort
Dose: cells
( 105)/cm
of lesion
Cells/mL
(mg particles/mL)
Total cells
(based on No.
of 3-mLa injections)
No. of injections
(3 mLa each)
Lesion
length (cm)
Approximate
cells/kgb
A (n ¼ 11) 6 7.8  105
(9)
4.7  106
7.0  106
2 (n ¼ 7)
3 (n ¼ 4)
7-10
11-15
6.3  104
9.5  104
B (n ¼ 10) 15 2.1  106
(25)
1.3  107
1.9  107
2 (n ¼ 4)
3 (n ¼ 6)
7-10
11-15
2.0  105
2.9  105
aInjection volume ranged from 3 to 4 mL.
bOn the basis of average body weight of cohort A (73.5 kg) and cohort B (65.3 kg).
Fig 3. Patient disposition and cohort participant ﬂow. Primary
and secondary outcome analysis was performed on all 21 PVS-
10200-treated patients. Patients who terminated before week 48
were asked to return for an early termination visit. One patient in
each cohort withdrew consent before the 48-week end point. AE,
Adverse event.
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Dilation was performed solely within the stented segment,
with up to 10% oversizing of the postdilation balloon.
Patients were treated with PVS-10200 at the conclu-
sion of the surgery. Each patient received two or three
injections spaced approximately 4 to 5 cm apart, depend-
ing on the length of the target lesion (previous preclinical
studies have demonstrated that a single 3-mL to 4-mL in-
jection provided a homogenous distribution of PVS-
10200 over a distance of approximately 4 to 5 cm).26,29
PVS-10200 was delivered percutaneously perpendicular
to the stent by ultrasound-guided injection perivascular
to the target lesion (Fig 2). Cell concentration per 3- to
4-mL injection increased with each cohort (Table I).
The lower dose was chosen because it was similar to a
cell dose of allogeneic human aortic ECs seeded on
gelatin matrices (Vascugel; Shire, San Diego, Calif), the
safety of which was conﬁrmed in a phase I/II clinical
trial.24 The higher dose was chosen because it was similar
to that used in preclinical toxicology and efﬁcacy studies
of PVS-10200.26
PVS-10200 was administered under ultrasound guid-
ance with the use of a customized syringe and an echogenic
needle (21-gauge/7 cm; Cook Medical, Bloomington,
Ind). Postsurgery vital signs and adverse events (AEs)
were recorded. After surgery, all patients received individu-
alized antiplatelet therapy according to the institution’s
standard of care. Follow-up assessments occurred 24 hours
after surgery and 4, 24, and 48 weeks thereafter. Assess-
ments at 24 hours included evaluation of the femoral access
and PVS-10200 administration sites, duplex ultrasound,
physical examination with vital signs, blood chemistries,
complete blood count, resting ankle-brachial index (ABI)
assessment, and Fontaine classiﬁcation. At weeks 4, 24,
and 48, assessments included physical examination with vi-
tal signs, resting ABI assessment, Fontaine classiﬁcation,
and duplex ultrasound. In addition, access and administra-
tion sites were evaluated at week 4, and radiography was
performed at week 48 to assess stent fracture. Panel-
reactive antibodies (PRA) were measured from serum sam-
ples obtained at screening and 48 weeks. Serum samples
were screened for PRA with the use of the Luminex plat-
form (Austin, Tex), which detects antibodies to human
leukocyte antigen by means of ﬂow cytometric technology.
PRA results on serum collected at screening and at the 48-
week visit were required to be included in the analysis.Safety monitoring and study outcomes. The primary
end point was incidence of major adverse events (MAEs)
within the ﬁrst 4 weeks after surgery, with MAEs deﬁned
as death, major amputation, procedurally related serious
AEs (SAEs; deﬁned as SAEs within 14 days of treatment
deemed directly related to the treatment application of
PVS-10200 by ultrasound-guided injection), and study
product-related (exclusive of stent placement) SAEs.
Relatedness of an SAE to the investigational product was
determined by the investigator and recorded on the SAE
form. All SAEs were reviewed by the data safety moni-
toring board members, who made the determination if an
SAE met the criteria for an MAE. Secondary end points,
evaluated at weeks 4, 24, and 48, were maintenance of
primary patency (deﬁned as duplex ultrasound peak systolic
velocity ratio #2.4), rate of binary restenosis (4-, 24-, and
48-week images compared with 24-hour postsurgery
image), time to reintervention of the target lesion, Fon-
taine class, incidence of MAEs (weeks 24 and 48), resting
ABI in the treated leg, incidence of SAEs and AEs, labo-
ratory abnormalities, and changes in physical examination.
Ultrasound images were reviewed and interpreted by an
Table II. Baseline characteristics of patients and lesions
Characteristic Cohort A (n ¼ 11) Cohort B (n ¼ 10) Total (N ¼ 21)
Age, years 61.6 6 10.11 70.7 6 7.67 66.0 6 9.96
Sex
Male 9 (81.8) 6 (60.0) 15 (71.4)
Female 2 (18.2) 4 (40.0) 6 (28.6)
Race
White 10 (90.9) 10 (100.0) 20 (95.2)
Black 1 (9.1) 0 1 (4.8)
Body mass index, kg/m2 25.1 6 3.94 24.7 6 4.34 24.9 6 4.04
Fontaine classiﬁcation
Stage IIB 10 (90.9) 6 (60.0) 16 (76.2)
Stage IV 1 (9.1) 4 (40.0) 5 (23.8)
ABI 0.683 6 0.198 0.522 6 0.115 0.611 6 0.181
Prior procedures/interventions
No 8 (72.7) 3 (30.0) 11 (52.4)
Yes 3 (27.3) 7 (70.0) 10 (47.6)
History
Diabetes mellitus/type 2 diabetes mellitus 4 (36.4) 8 (80.0) 12 (57.1)
Dyslipidemia 7 (63.6) 6 (60.0) 13 (61.9)
Hypertension 9 (81.8) 7 (70.0) 16 (76.2)
Cardiac disorders 5 (45.5) 2 (20.0) 7 (33.3)
Antithrombotic agents 11 (100.0) 10 (100.0) 21 (100.0)
Lipid-modifying agents 11 (100.0) 10 (100.0) 21 (100.0)
Systemic antibacterial agents 10 (90.9) 9 (90.0) 19 (90.5)
Nicotine dependence 11 (100.0) 8 (80.0) 19 (90.5)
Degree of stenosis
Complete occlusion 4 (36.4) 5 (50.0) 9 (42.9)
90% stenosis 5 (45.5) 4 (40.0) 9 (42.9)
80% stenosis 0 1 (10.0) 1 (4.8)
70% stenosis 2 (18.2) 0 2 (9.5)
Size of target lesion, cm 9.45 6 2.11 10.80 6 2.53 10.10 6 2.36
Range, cm 7-13 7-15 7-15
Severe calciﬁcation
No 8 (72.7) 5 (50.0) 13 (61.9)
Yes 3 (27.3) 5 (50.0) 8 (38.1)
Target vessel diameter, mm 5.63 6 0.52 5.11 6 0.78 5.35 6 0.70
Stent diameter, mm 6.36 6 0.50a 6.0 6 0.0a 6.19 6 0.40
Oversize ratio 1.14 6 0.09 1.20 6 0.19 1.17 6 0.15
ABI, Ankle-brachial index.
Continuous data are presented as mean 6 standard deviation and categorical data as number (%).
aCohort A patients received 6- or 7-mm-diameter stents; cohort B patients received 6-mm-diameter stents.
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Statistical methods. The sample size was selected to
provide safety and usage data to support a determination
of PVS-10200 dosage concentration(s) to be evaluated in
future clinical trials. Statistical analyses were descriptive in
nature. For continuous variables, mean, standard deviation,
median, and range were provided. For categorical variables,
frequency and percentage per class were provided. Two-
sided 95% conﬁdence intervals were used when required.
No imputation methods to account for missing data were
applied. Freedom fromMAEs and time to reintervention of
the target lesion/vessel were analyzed by means of the
Kaplan-Meier method. Safety and efﬁcacy analyses were
conducted on all subjects treated with PVS-10200.
RESULTS
Patient population. A total of 30 patients provided
written informed consent and were screened for studyeligibility (Fig 3). Of these, 21 met the eligibility criteria
and were enrolled in the study (cohort A, n ¼ 11; cohort B,
n ¼ 10). Review of safety data revealed that PVS-10200
was well tolerated in all patients, with no safety concerns
identiﬁed in either cohort. Baseline characteristics of the
two cohorts are listed in Table II. Fontaine classiﬁcation,
ABI, severe calciﬁcation, and prior procedures at baseline
suggested more severe disease in cohort B compared with
cohort A. All patients were receiving antithrombotic and
lipid-modifying agents. The mean length of the target
lesion was 10.1 6 2.36 cm and $70% stenosis; with 42.9%
of patients presenting with occlusion at baseline. In cohort
A, the mean target lesion was 9.45 6 2.11 cm (median,
8.00 cm); seven patients received two PVS-10200
injections (63.6%) and four patients received three in-
jections (36.4%). In cohort B, the mean target lesion was
10.806 2.53 cm (median, 11.50 cm); four and six patients
were administered two (40.0%) and three (60.0%) PVS-
10200 injections, respectively.
Fig 4. Improvement in clinical status for cohort A and cohort B
patients. A, Mean ankle-brachial index (ABI) over 48 weeks. The
error bars represent standard deviation. The mean percent change
from baseline for cohort A was 47.7%6 40.1% and 37.2%6 42.7%
at 24 and 48 weeks, respectively. The mean percent change from
baseline for cohort B was 64.9%6 51.5% and 62.1%6 70.9% at 24
and 48 weeks, respectively. B, Fontaine classiﬁcation (I ¼ asymp-
tomatic; IIA ¼ mild claudication; IIB ¼ moderate-severe claudi-
cation; IV ¼ ulceration or gangrene) for cohort A over 48 weeks;
80% and 70% of patients maintained an improvement of $1 Fon-
taine stage at 24 and 48 weeks, respectively. C, Fontaine classiﬁca-
tion for cohort B over 48 weeks; 62.5% and 77.8% of patients had
improved by $1 Fontaine stage at 24 and 48 weeks, respectively.
Table III. Most common treatment-emergent adverse
events (TEAEs) (regardless of relationship to study drug/
procedure)
Cohort A
(n ¼ 11)
Cohort B
(n ¼ 10)
Total
(N ¼ 21)
At least one TEAE 11 (100.0) 10 (100.0) 21 (100.0)
Intermittent claudication 6 (54.5) 2 (20.0) 8 (38.1)
In-stent arterial restenosis 3 (27.3) 3 (30.0) 6 (28.6)
Hypertension 4 (36.4) 0 4 (19.0)
Ecchymosis 1 (9.1) 3 (30.0) 4 (19.0)
Data are reported as number (%) of subjects. Incidence $10% overall during
the 48-week follow-up period.
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hort had an MAE within 24 weeks after treatment with
PVS-10200. One patient in cohort B had an MAE be-
tween 24 and 48 weeks after treatment. This patient was an
84-year-old woman with a 27-year history of PAD, who
had a Fontaine classiﬁcation of stage IV, an occlusion of the
right SFA, and toe amputation before study surgery and
PVS-10200 treatment. At week 30, she required amputa-
tion of the target leg because of necrosis of the right foot.
Although no healing of the necrosis was expected, revas-
cularization was performed to secure below-the-knee
amputation. The event led to her withdrawal from the
study. The investigator considered the event unrelated to
the study product and the study procedure.
All 21 (100%) patients had a total of 61 treatment-
emergent AEs (TEAEs) during the study. The most com-
mon TEAEs reported during the study are presented in
Table III. All TEAEs considered related to study drug/
study procedure were mild in intensity. All severe TEAEs
were considered to be unrelated to the study product or
procedure. A total of 14 (66.7%) patients had an SAE
(63.6% [cohort A]; 70.0% [cohort B]). The most common
treatment-emergent SAEs (n > 1) that occurred in cohort
A and cohort B, respectively, were in-stent arterial resteno-
sis (27.3%, 30.0%), arterial restenosis (18.2%, 0%), intermit-
tent claudication (18.2%, 0%), and toe amputation (0%,
10.0%). None of the SAEs were considered to be related
to study drug/procedure, and no deaths were reported
during the follow-up period.
Secondary efﬁcacy outcomes. Treatment with PVS-
10200 after successful angioplasty and stent placement
resulted in improvement from baseline in clinical status,
deﬁned as change in resting ABI in the target leg and Fon-
taine class (Fig 4). Improvement in ABI was observed at 4
and 24 weeks, with a 37% and 62% improvementmaintained
through 48 weeks after surgery for cohorts A and B,
respectively. At week 48, 74% of all patients (70% cohort A
and 78% cohort B) had improved by $1 Fontaine classiﬁ-
cation stage from baseline, with 58% of patients (60% cohort
A and 56% cohort B) classiﬁed as stage I (asymptomatic).
One patient was classiﬁed as stage IV (ulceration or
gangrene) at week 48; however, this patient also was classi-
ﬁed as stage IV at screening. Primary patency (Table IV) was
maintained for 53% of patients at week 24 (56% [cohort A]and 50% [cohort B]) and 54% of patients at week 48 (57%
[cohort A] and 50% [cohort B]). In-stent binary restenosis
rates (Table IV) in cohorts A and B were 44% and 50% at
week 24 and 50% and 43% at week 48, respectively.
A retrospective analysis of the secondary efﬁcacy end
points was performed on the basis of target lesion length.
Patients were divided into two groups: <10-cm (n ¼ 10)
Table IV. Duplex ultrasound diagnostic data by dose cohort
Parameter
Day 2 Week 4 Week 24 Week 48
Cohort A Cohort B Cohort A Cohort B Cohort A Cohort B Cohort A Cohort B
Primary patency (yes),
n/No. (%)a
8/8 (100.0) 9/9 (100.0) 9/9 (100.0) 9/9 (100.0) 5/9 (55.6) 4/8 (50.0) 4/7 (57.1) 3/6 (50.0)
In-stent binary
restenosis (50%-99%),
n/No. (%)b
0/9 (0.00) 0/9 (0.0) 0/9 (0.0) 0/9 (0.0) 4/9 (44.4) 4/8 (50.0) 4/8 (50.0) 3/7 (43.0)
aPrimary patency was deﬁned as duplex ultrasound peak systolic velocity ratio$2.4. Only ultrasound data that were considered diagnostic and evaluable by the
core laboratory were included.
bBinary restenosis was a yes/no assessment, with 0% to 49% ¼ no (peak systolic velocity ratio #2.4) and 50% to 99% ¼ yes (peak systolic velocity ratio >2.4);
the peak systolic velocity ratio was calculated as peak systolic velocity from stenosis divided by the peak systolic velocity from a normal segment of artery
proximal to the stenosis. Only ultrasound data that were considered diagnostic and evaluable by the core laboratory were included.
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greater proportion of those with $10-cm lesion length
were treated in cohort B (64% compared with 30% of
the <10-cm lesion group). Improvement in resting ABI in
the target leg was maintained by 41% and 54% from baseline
for <10-cm and $10-cm lesions, respectively, at 48 weeks
(Fig 5). Fontaine classiﬁcation had also improved by$1 stage
in 88% of patients with <10-cm lesions and 64% of patients
with $10-cm lesions (Fig 5). Primary patency was main-
tained for 60% and 50% of patients with lesions <10 cm
and $10 cm, respectively, at 48 weeks (Table V). The in-
stent binary restenosis rates were 50% and 44% for patients
with lesions <10 cm and $10 cm, respectively (Table V).
A total of 30% of patients required target lesion revasculariza-
tion (TLR) within 48 weeks. Kaplan-Meier analysis of the
time to TLR is reported in Figs 6 and 7.
Secondary safety outcomes. Secondary safety end
points of the study were clinical laboratory evaluations,
including measuring the development of PRA over time
and assessing stent integrity. No clinically relevant changes
from baseline were observed for vital signs, hematology, or
clinical chemistry parameters. Of 21 patients, 14 had serum
collected and analyzed for PRA at both the screening and
week-48 visits. Twelve of the patients were negative for
PRA at week 48. Two of the 14 (both in cohort A) were
positive for PRA atweek 48; however, theywere also positive
at screening (class I or both class I and class II), that is,
sensitized before study drug exposure. No patient who was
negative for PRA at screening was positive at week 48. Ra-
diographs of the stents obtained at week 48 were compared
with the intervention radiograph and showed no evidence of
stent fracture, with good integrity of the stent reported.
DISCUSSION
The primary end point of the study was met, with no
patient having an MAE at 4 weeks after surgery. One
MAE in the target leg occurred at 30 weeks after surgery
and was considered by the investigator to be unrelated to
the study product and study procedure. The most common
TEAEs were intermittent claudication, in-stent arterial
restenosis, hypertension, and ecchymosis and were not un-
expected, given the indication being studied. There were a
few differences in the incidence of TEAEs in the low- andhigh-dose cohorts: hypertension (36.4% and 0%, respec-
tively), ecchymosis (9.1% and 30.0%, respectively), and
intermittent claudication (54.5% and 20%, respectively);
however, the small sample size precluded determination
of signiﬁcance. No deaths were reported, and no patient
had an SAE that was considered to be related to the study
product/procedure at any time during the follow-up
period. In addition, there was no increase in humoral sensi-
tization after treatment with PVS-10200 and no apparent
safety concerns between the low-dose and high-dose
administration of PVS-10200.
Overall, stent placement and PVS-10200 administra-
tion procedures were well tolerated. Examination of study
product injection sites showed that most patients had no
reactions, and those who did had only mild reactions. No
patient had erythema, inﬂammation, or induration at either
the access or injection site. The ultrasound-guided delivery
technique of the product was reproducible for all investiga-
tors at each center, with 100% delivery success perivascular
to the stented vessel.
The present study was not designed to detect efﬁcacy.
However, review of the secondary end point data showed
that treatment with PVS-10200 after successful angioplasty
and stent placement resulted in improvement from baseline
in clinical status (including primary patency, Fontaine clas-
siﬁcation, and resting ABI), which was maintained for most
patients through 48 weeks after treatment. There was no
signiﬁcant difference in lesion length between cohorts A
and B; however, patients in the high-dose cohort B main-
tained a greater improvement in ABI, Fontaine class, and
TLR at 48 weeks compared with cohort A. In addition,
the 44% restenosis and 18% TLR rates at 48 weeks for
those patients in this study with $10-cm target lesions
are similar to or slightly better than those reported in the
literature (>70% restenosis and >40% TLR) for stenting
of long SFA lesions.3,30 This may be due to a greater pro-
portion of patients in the $10-cm lesion group being
treated in cohort B and receiving the highest dose of
PVS-10200, which is similar to the dose previously shown
to be efﬁcacious in animal studies.26
Thrombosis, inﬂammation, and SMC proliferation that
can occur after endovascular interventions result in signiﬁcant
obstruction to the blood vessel lumen. The endothelial
Fig 5. Improvement in clinical status by lesion length. A, Mean
ankle-brachial index (ABI) over 48 weeks. The error bars represent
standard deviation. The mean percent change from baseline for
patients with lesions <10 cm was 52.6% 6 46.3% and 40.7% 6
45.2% at 24 and 48 weeks, respectively. The mean percent change
from baseline for patients with lesions$10 cm was 56.8%6 46.2%
and 53.9% 6 65.5% at 24 and 48 weeks, respectively. B, Fontaine
classiﬁcation (I ¼ asymptomatic; IIA ¼ mild claudication; IIB ¼
moderate-severe claudication; IV ¼ ulceration or gangrene) for
patients with lesions <10 cm over 48 weeks; 57% and 87.5% of
patients maintained an improvement of $1 Fontaine stage at 24
and 48 weeks, respectively. C, Fontaine classiﬁcation for patients
with lesions $10 cm; 81.8% and 63.6% of patients had improved
by $1 Fontaine stage at 24 and 48 weeks, respectively.
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approach to addressing the complications associated with pe-
ripheral interventions. Preclinical studies have shown that
when injected by ultrasound visualization to the outside of a
stented femoral artery, at the adventitia, tissue-engineeredECs decreased inﬂammation, stenosis, and increased lumen
diameter.26 A purported mechanism is that EC-secreted
productsmove throughout thebloodvesselwall andmay alter
the bioavailability and distribution of endogenous vasoregula-
tory compounds.22,31 These studies provided the basis for the
clinical development of PVS-10200 as a minimally invasive,
locally applied, perivascular therapy to improve the outcome
at sites of vascular interventions.
Because the cells used to formulate PVS-10200 are
allogeneic, patients were monitored for sensitization
through measurement of the development of human
leukocyte antigen antibodies. No patient tested for PRA
at 48 weeks was sensitized when compared with their base-
line level. Multiple in vitro and in vivo immunological
studies have demonstrated that culturing ECs in vitro on
gelatin matrices before implantation in vivo attenuates
the immunogenicity of the cells, thus allowing for their im-
plantation without triggering signiﬁcant host-immune re-
actions.32,33 However, because PRA was obtained only at
baseline and at 48 weeks, increases in PRA at other time
points could not be detected.
The present study had several limitations. It was
designed as a small safety and feasibility study of a novel
tissue-engineered cellular injectable product and therefore
was not designed to detect therapeutic beneﬁt. In addition,
because the study did not include a control arm, analysis
and interpretation of efﬁcacy data and/or trends is limited.
However, the lesions treated in the present study (10.1 6
2.36 cm) were considered to be at high risk for in-stent
restenosis because they were long, severe, and calciﬁed
(85.8% of lesions were$90% occluded). The clinical results
were satisfactory, with a sustained objective improvement
of ABI at 48 weeks and of Fontaine classiﬁcation for 74%
of patients. However, because all subjects were treated
with PVS-10200 after successful angioplasty and stent
placement, the effects that may have been caused by
PVS-10200 alone could not be determined. In addition,
missing or unevaluable ultrasound and PRA data decreased
an already-limited data set.
CONCLUSIONS
Minimally invasive, local delivery of PVS-10200 is a
novel approach that is well tolerated and may be a suitable
treatment for patients after endovascular intervention of
the SFA. In addition, delivery of PVS-10200 at the adven-
titia not associated with delivery of the stent itself may have
application in clinical settings where stent placement is not
feasible, such as in arteries located below the knee. Devel-
opment of an endovascular delivery approach, which could
expand the potential use, is ongoing. Larger, randomized,
multicenter studies are necessary to further the current
ﬁndings and demonstrate the efﬁcacy of PVS-10200 on
the prevention of restenosis and on the clinical improve-
ment of patients with severe lesions of the SFA.
The authors wish to acknowledge Professor Philippe
Menasche for his role in identifying the study centers and
Professor Gilles Chatellier, Professor Pascal Desgranges,
Table V. Duplex ultrasound diagnostic data by lesion lengtha
Parameter
Day 2 Week 4 Week 24 Week 48
<10 cm $10 cm <10 cm $10 cm <10 cm $10 cm <10 cm $10 cm
Primary patency
(yes), n/No. (%)b
7/7 (100.0) 10/10 (100.0) 7/7 (100.0) 11/11 (100.0) 2/6 (33.3) 7/11 (63.6) 3/5 (60) 4/8 (50)
In-stent restenosis
binary (50% to 99%),
n/No. (%)c
0/7 (0.0) 0/11 (0.0) 0/7 (0.0) 0/11 (0.0) 4/6 (66.7) 4/11 (36.4) 3/6 (50.0) 4/9 (44.4)
aIn cohort A, 63.6% of patients had <10-cm lesions, 36.3% had $10-cm lesions; 30% of cohort B patients had <10-cm lesions, 70% had $10-cm lesions.
bPrimary patency was deﬁned as duplex ultrasound peak systolic velocity ratio$2.4. Only ultrasound data that were considered diagnostic and evaluable by the
core laboratory were included.
cBinary restenosis was a yes/no assessment, with 0% to 49% ¼ no (peak systolic velocity ratio #2.4) and 50% to 99% ¼ yes (peak systolic velocity ratio >2.4);
the peak systolic velocity ratio was calculated as peak systolic velocity from stenosis divided by the peak systolic velocity from a normal segment of artery
proximal to the stenosis. Only ultrasound data that were considered diagnostic and evaluable by the core laboratory were included.
Fig 6. Kaplan-Meier event analyses of target lesion revasculariza-
tion (TLR) by dose cohort; 60.6% survival for low-dose cohort A
vs 80% survival for high-dose cohort B. A total of 30% of patients
required TLR within 48 weeks. SE, Standard error.
Fig 7. Kaplan-Meier event analyses of target lesion revasculariza-
tion (TLR) by lesion length; 56.3% survival for lesions <10 cm vs
82% survival for lesions $10 cm. A total of 30% of patients
required TLR within 48 weeks. SE, Standard error.
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